CARsgen Therapeutics

Company Drug

CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina

Fineline Cube Sep 2, 2022

China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...

Company Deals

Porton Advanced Partners with T&L Biotechnology – CGT One-Stop Solution Targets Global Cell and Gene Therapy Market

Medical Device

China NMPA Approves World’s First Invasive BCI Medical Device – Brain-Computer Interface Hand Motor System Targets Spinal Cord Injury Patients

Company Drug

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Company Drug

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers